Cliff Asness's CADL Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 18,028 shares of Candel Therapeutics, Inc. (CADL) worth $88,338, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 6 quarters.
Based on 13F filings, Cliff Asness has maintained this position in CADL for several quarters, showing initial confidence in the investment. Largest addition occurred in Q1 2026, adding 18,028 shares. Largest reduction occurred in Q3 2025, reducing 19,261 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Candel Therapeutics (CADL) Holding Value Over Time
Track share changes against reported price movement
Quarterly Candel Therapeutics (CADL) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +18,028 | New Buy | 18,028 | $4.90 |
| Q3 2025 | -19,261 | Sold Out | 0 | $0.00 |
| Q2 2025 | -1,757 | Reduce 8.36% | 19,261 | $5.06 |
| Q1 2025 | -841 | Reduce 3.85% | 21,018 | $5.65 |
| Q4 2024 | +1,823 | Add 9.10% | 21,859 | $8.68 |
| Q3 2024 | +20,036 | New Buy | 20,036 | $6.93 |
Cliff Asness's Candel Therapeutics Investment FAQs
Cliff Asness first purchased Candel Therapeutics, Inc. (CADL) in Q3 2024, acquiring 20,036 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Candel Therapeutics, Inc. (CADL) for 6 quarters since Q3 2024.
Cliff Asness's largest addition to Candel Therapeutics, Inc. (CADL) was in Q3 2024, adding 20,036 shares worth $138,849.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 18,028 shares of Candel Therapeutics, Inc. (CADL), valued at approximately $88,338.
As of the Q1 2026 filing, Candel Therapeutics, Inc. (CADL) represents approximately 0.00% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Candel Therapeutics, Inc. (CADL) was 21,859 shares, as reported at the end of Q4 2024.